同步放化疗对不能手术局部晚期胃癌的疗效

目的:观察同步放化疗对不能手术的局部胃癌晚期（Ⅱ-Ⅲc）患者的近期疗效。方法:将55例不能手术的局部晚期胃癌患者随机分为2组，28例进行同步放化疗治疗，先行XELOX方案化疗1周期，于2周期化疗第2天同时进行适形放疗，并按化疗周期进行3、4周期XELOX方案治疗。27例患者进行4周期XELOX方案化疗。结果:无进展生存期（PFS）:同步放化疗组为7.11个月，化疗组为5.13个月 (P＜0.05)；一年生存率同步放化疗组60%高于化疗组51%，两者比较，无统计学意义(P＞0.05)；肿瘤客观缓解率（ORR）同步放化疗组67.8%，化疗组40.7%（P＜0.05）；患者卡氏评分两组治疗前后均无统计学意义(P＞0.05)。结论:同步放化疗可以提高不能手术局部晚期胃癌患者近期疗效。

Efficacy of chemoradiation in the advanced gastric carcinoma patients without operation

Objective:To investigate the efficacy of advanced gastric carcinoma patients (Ⅱ- Ⅲc) received only chemoradiotherapy without operation.Methods:All 55 cases with locally advanced gastric cancer who can not accepted operation were randomly divided into two groups,After treated with XELOX scheme 1 cycle of chemotherapy,28 patients accepted 3-dimensional conformal radiation therapy in the second day of the next cycle of chemotherapy and chemotherapy cycle XELOX regimen for 3,4 cycle.27 patients received XELOX scheme chemotherapy for 4 cycles.Results:The median progress free survival (PFS) of chemoradiotherapy group was 7.11 months while the chemotherapy group was 5.13 months.There were statistical significance between the two groups(P＜0.05).The 1 year survival rate was 60% in the concurrent chemoradiotherapy group and 51% in the chemotherapy group.There were no statistical significance.The objective response rates of tumor (ORR) were 67.8% and 40.7%,respeccivelly（P＜0.05）.The KPS score of the two groups had no statistical significance prior and post treatment (P＞0.05).Conclusion:The chemoradiotherapy can improve the efficacy of locally advanced gastric carcinoma patients (Ⅱ-Ⅲc) without operation.